Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AVITA MEDICAL, INC. reported revenue of $72M, up 11.5% year over year. Operating margin was -59.4% and net margin -67.8%, on a free-cash-flow margin of -45.0% with capital expenditure at 1.4% of revenue. Every figure is computed directly from RCEL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $72M | -59.4% | -67.8% |
| FY2024 | $64M | -88.1% | -96.3% |
| FY2023 | $50M | -85.1% | -70.6% |
| FY2022 | $34M | -79.9% | -77.5% |
| FY2021 | $29M | -90.8% | -90.9% |
How does RCEL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.